Synergistic Interaction between 5-FU and an Analog of Sulforaphane-2-Oxohexyl Isothiocyanate-In an In Vitro Colon Cancer Model.
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Autophagy
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
Colonic Neoplasms
/ pathology
Drug Synergism
Fluorouracil
/ pharmacology
Humans
In Vitro Techniques
Isothiocyanates
/ chemistry
Models, Biological
Sulfoxides
/ chemistry
Thiocyanates
/ chemistry
5-fluorouracil
isothiocyanates
sulforaphane
synergistic effect
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
19 May 2021
19 May 2021
Historique:
received:
20
04
2021
revised:
14
05
2021
accepted:
16
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
27
7
2021
Statut:
epublish
Résumé
Combination therapy is based on the beneficial effects of pharmacodynamic interaction (synergistic or additive) between combined drugs or substances. A considerable group of candidates for combined treatments are natural compounds (e.g., isothiocyanates) and their analogs, which are tested in combination with anticancer drugs. We tested the anticancer effect of the combined treatment of isothiocyanate 2-oxohexyl isothiocyanate and 5-fluorouracil in colon and prostate cancer cell lines. The type of interaction was described using the Chou-Talalay method. The cytostatic and cytotoxic activities of the most promising combined treatments were investigated. In conclusion, we showed that combined treatment with 5-fluorouracil and 2-oxohexyl isothiocyanate acted synergistically in colon cancer. This activity is dependent on the cytostatic properties of the tested compounds and leads to the intensification of their individual cytotoxic activity. The apoptotic process is considered to be the main mechanism of cytotoxicity in this combined treatment.
Identifiants
pubmed: 34069385
pii: molecules26103019
doi: 10.3390/molecules26103019
pmc: PMC8158758
pii:
doi:
Substances chimiques
2-oxohexyl isothiocyanate
0
Antineoplastic Agents
0
Isothiocyanates
0
Sulfoxides
0
Thiocyanates
0
sulforaphane
GA49J4310U
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Science Center
ID : N/NZ5/02634
Références
Nutrients. 2015 Jan 23;7(2):799-814
pubmed: 25625815
Tumour Biol. 2016 Apr;37(4):4479-91
pubmed: 26496737
Oncogene. 2004 Sep 2;23(40):6702-11
pubmed: 15273734
PLoS One. 2018 Mar 8;13(3):e0193918
pubmed: 29518137
Basic Clin Pharmacol Toxicol. 2007 Oct;101(4):277-85
pubmed: 17845510
Food Chem Toxicol. 2020 Sep;143:111529
pubmed: 32619557
Int J Cancer. 2008 Jan 15;122(2):267-73
pubmed: 17918158
Am J Cancer Res. 2020 Mar 01;10(3):799-815
pubmed: 32266092
Food Chem Toxicol. 2018 Jan;111:1-8
pubmed: 29104175
Chin Med J (Engl). 2016 Feb 20;129(4):456-63
pubmed: 26879020
Croat Med J. 2006 Dec;47(6):832-40
pubmed: 17167855
Molecules. 2018 Nov 21;23(11):
pubmed: 30469330
Chang Gung Med J. 2003 Apr;26(4):250-8
pubmed: 12846524
Int J Med Sci. 2017 Apr 7;14(4):356-366
pubmed: 28553168
Aging (Albany NY). 2016 Apr;8(4):603-19
pubmed: 27019364
J Clin Oncol. 2004 Sep 15;22(18):3766-75
pubmed: 15365073
F1000Prime Rep. 2015 Feb 03;7:18
pubmed: 25750736
Cold Spring Harb Perspect Biol. 2013 Jun 01;5(6):
pubmed: 23732469
Cancer Chemother Pharmacol. 2011 May;67(5):1167-78
pubmed: 20689952
Cancer Lett. 2004 Nov 8;215(1):53-9
pubmed: 15374632
Oncol Rep. 2005 Apr;13(4):659-65
pubmed: 15756439
Biochem Biophys Res Commun. 2017 Sep 9;491(1):209-216
pubmed: 28712871
Clin Colorectal Cancer. 2015 Mar;14(1):1-10
pubmed: 25579803
Oncol Rep. 2003 Nov-Dec;10(6):2045-50
pubmed: 14534741
Biochem Biophys Res Commun. 2005 Jul 1;332(2):433-40
pubmed: 15896711
Oncotarget. 2017 Jun 6;8(23):38022-38043
pubmed: 28410237
Oncol Lett. 2014 Aug;8(2):699-704
pubmed: 25013487
Cochrane Database Syst Rev. 2017 Jul 28;7:CD008398
pubmed: 28752564
Adv Enzyme Regul. 1984;22:27-55
pubmed: 6382953
Sci Rep. 2020 Jan 23;10(1):1063
pubmed: 31974389
Mol Cancer Ther. 2016 Dec;15(12):2863-2874
pubmed: 27765854
Sci Rep. 2020 Sep 17;10(1):15234
pubmed: 32943650
Cancer Biol Ther. 2008 Aug;7(8):1305-12
pubmed: 18497562
Mol Cell Biol. 2009 Aug;29(16):4431-40
pubmed: 19528225
Apoptosis. 1998 Mar;3(2):115-21
pubmed: 14646509
Nat Rev Cancer. 2006 Jul;6(7):546-58
pubmed: 16794637
Oncol Rep. 2017 Jan;37(1):594-600
pubmed: 27878254
Mol Ther. 2011 Jan;19(1):188-95
pubmed: 20940707
Helv Chim Acta. 1948 Oct 15;31(6):1497-1505
pubmed: 18104419
Cell Death Dis. 2020 Jun 24;11(6):477
pubmed: 32581212
Ther Adv Med Oncol. 2010 Nov;2(6):381-8
pubmed: 21789149
Acta Pol Pharm. 2011 May-Jun;68(3):331-42
pubmed: 21648187
J Environ Pathol Toxicol Oncol. 2009;28(4):269-82
pubmed: 20102325
World J Gastrointest Oncol. 2014 Jun 15;6(6):177-83
pubmed: 24936228
Food Funct. 2015 May;6(5):1460-9
pubmed: 25857357
Cell Death Differ. 2018 Mar;25(3):486-541
pubmed: 29362479
Sci Rep. 2020 Nov 18;10(1):20030
pubmed: 33208761
Cancer Chemother Pharmacol. 2015 Sep;76(3):575-86
pubmed: 26208739
J Cell Biochem. 2010 Jul 1;110(4):893-902
pubmed: 20564188
Nutr Cancer. 2015;67(2):275-84
pubmed: 25622112